Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962026 · ClinicalTrials.gov registry record · Phase 1
Rilonacept in Diabetes Mellitus Type 1: Safety Study
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00962026 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 13 participants.
The verdict
NCT00962026, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is being done to see if an investigational drug called rilonacept is safe to use in patients with type 1 diabetes, and if it can slow the loss of the body's ability to secrete insulin in patients who are still able to make a small amount of insulin.
Interventions
- DRUG Rilonacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00962026
The ClinicalTrials.gov registry entry for NCT00962026 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rilonacept is the first listed.
NCT00962026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00962026 about?
NCT00962026 is a clinical study titled "Rilonacept in Diabetes Mellitus Type 1: Safety Study". This study is being done to see if an investigational drug called rilonacept is safe to use in patients with type 1 diabetes, and if it can slow the loss of the body's ability to secrete insulin in patients who are still able to make a small amount of insulin.
What is the current status of trial NCT00962026?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2011-02. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00962026?
The interventions under investigation include: Rilonacept (DRUG).
Who is sponsoring clinical trial NCT00962026?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.